"Because they still have the problem," he said. "The obesity is just a symptom." On a more macro level, Novo Nordisk's ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk bread and butter diabetes and obesity drugs obscure its other remedies for estrogen replacement, wound treatment ...

Novo Nordisk shares were up Wednesday following an earnings report that showed continued sales growth of its obesity drug.

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The ...

Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt last quarter as it became available in more ...

Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...